Table 3 Therapeutic intervention and outcomes of all neonatal ventilator-associated pneumonia (VAP) in the CGMH, October 2017-March 2020
Characteristics | All VAP episodes (total n = 236) | Monomicrobial VAP episodes (total n = 176) | Polymicrobial VAP episodes (total n = 60) | P values |
|---|---|---|---|---|
Therapeutic intervention, n (%) | Â | Â | Â | Â |
 Initial empiric antibiotics |  |  |  |  |
  Inappropriate initial antibiotics | 74 (31.4) | 49 (27.8) | 25 (41.7) | 0.054 |
  Use of first line antibiotics | 58 (24.6) | 47 (26.7) | 11 (18.3) | 0.116 |
  Use of broad-spectrum antibiotics | 178 (75.4) | 129 (73.3) | 49 (81.7) | 0.116 |
 Modification of therapeutic antibiotics | 120 (50.8) | 82 (46.6) | 38 (63.3) |  < 0.001 |
 Therapeutic antibiotics |  |  |  |  |
  Use of first line antibiotics | 72 (30.5) | 52 (29.5) | 20 (33.3) | 0.627 |
  Use of broad-spectrum antibiotics | 164 (69.5) | 124 (70.5) | 40 (66.7) | 0.627 |
Duration of antibiotic treatment (day), mean ± SD | 9.6 ± 3.8 | 9.6 ± 3.8 | 9.8 ± 3.8 | 0.566 |
Therapeutic outcomes, n (%) | Â | Â | Â | Â |
 Detailed clinical assessment, n (%) |  |  |  | 0.503 |
  Clinical resolution | 91 (38.5) | 66 (37.5) | 25 (41.7) |  |
  Delayed resolution | 73 (30.9) | 56 (31.8) | 17 (28.3) |  |
  Relapse or recurrent infection | 20 (8.5) | 15 (8.5) | 5 (8.3) |  |
  Superinfection | 41 (17.4) | 30 (17.0) | 11 (18.3) |  |
  Death | 11 (4.7) | 9 (5.1) | 2 (3.3) |  |
 Detailed microbial assessment, n (%) |  |  |  | 0.462 |
  Resolution | 112 (47.5) | 84 (47.7) | 28 (46.7) |  |
  Relapsed or recurrent infection | 35 (14.8) | 29 (16.5) | 6 (10.0) |  |
  Superinfection | 72 (30.5) | 49 (27.8) | 23 (38.3) |  |
  Clinical failure | 17 (7.2) | 14 (8.0) | 3 (5.0) |  |
 Overall clinical assessment, n (%) |  |  |  | 0.414 |
  Cure | 200 (84.7) | 147 (83.5) | 53 (88.3) |  |
  Treatment failurea | 36 (15.3) | 29 (16.5) | 7 (11.7) |  |